Quattro Financial Advisors LLC Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Quattro Financial Advisors LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 88,135.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,000 shares of the biopharmaceutical company’s stock after buying an additional 44,949 shares during the quarter. Quattro Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,440,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BMY. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $34,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Finally, Fairman Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $42,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BMY shares. BMO Capital Markets lowered their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Barclays lowered their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded down $0.84 during trading on Tuesday, hitting $40.46. The stock had a trading volume of 18,275,301 shares, compared to its average volume of 15,773,156. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The firm has a market cap of $82.02 billion, a P/E ratio of -13.10, a PEG ratio of 14.21 and a beta of 0.44. The business has a fifty day moving average of $42.81 and a two-hundred day moving average of $48.04. Bristol-Myers Squibb has a fifty-two week low of $39.63 and a fifty-two week high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.93%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.